Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Mullazehi, Mohammed ^a   Wick, Marius C ^c   Klareskog, Lars ^b   van Vollenhoven, Ronald ^b   Rönnelid, Johan ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 1BETA; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR; VIMENTIN; AUTOANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT RADIOGRAPHY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IN VITRO STUDY; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; RHEUMATOID ARTHRITIS; AGED; BLOOD; IMMUNOLOGY; MIDDLE AGED; RADIOGRAPHY;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COLLAGEN TYPE II; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84860272864     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3825     Document Type: Article

References (24)

1. Valdimarsson H, Jonsson T. Predictive value of rheumatoid factor isotypes for radiological progression in patients with rheumatoid arthritis. Scand J Rheumatol 1996, 25:189-190. 10.3109/03009749609080015, 8668967.
2. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835. 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6, 10943873.
3. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089. 10.1136/ard.2003.016808, 1755123, 15308517.
4. Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511. 10.1002/art.22817, 17665451.
5. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiological progression as compared to antibodies against cyclic citrullinated peptide (anti-CCP). Arthritis Rheum 2008, 58:36-45. 10.1002/art.23188, 18163519.
6. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven R. Longitudinal analysis of anti-citrullinated protein/peptide antibodies (anti-CP) during 5 year follow-up in early rheumatoid arthritis: anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 10.1136/ard.2004.033571, 1755292, 15843452.
7. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. High anti-collagen type II antibody levels and induction of pro-inflammatory cytokines by anti-collagen antibody containing immune complexes in vitro characterize a distinct RA phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis 2007, 66:537-541. 1856042, 17040962.
8. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound anti-type II collagen containing immune complexes induce production of TNF-a, IL-1ß and IL-8 from peripheral blood monocytes via FcgRIIa. A potential patho-physiological mechanism for humoral anti-collagen type II immunity in RA. Arthritis Rheum 2006, 54:1759-1771. 10.1002/art.21892, 16736518.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
10. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977, 18:481-491.
11. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995, 22:1974-1975.
12. van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol 1999, 26:726-730.
13. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132.
14. Nandakumar KS, Bajtner E, Hill L, Bohm B, Rowley MJ, Burkhardt H, Holmdahl R. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008, 58:184-196. 10.1002/art.23049, 18163493.
15. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749. 10.1002/art.11223, 14558078.
16. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Rönnelid J, Rantapää-Dahlqvist S. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R13. 10.1186/ar3237, 3241357, 21291540.
17. Möttönen T, Hannonen P, Oka M, Rautiainen J, Jokinen I, Arvilommi H, Palosuo T, Aho K. Antibodies against native type II collagen do not precede the clinical onset of rheumatoid arthritis. Arthritis Rheum 1988, 31:776-779. 10.1002/art.1780310612, 3382450.
18. Pereira RS, Black CM, Duance VC, Jones VE, Jacoby RK, Welsh KI. Disappearing collagen antibodies in rheumatoid arthritis. Lancet 1985, 2:501-502.
19. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009, 60:2262-2271. 10.1002/art.24661, 19644846.
20. Bhagat S, Ostor AJ. Diagnosing joint pain in the older people. Practitioner 2010, 254:17-21. 12.
21. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH, Cho CS, Kim HY. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000, 27:575-581.
22. Mathsson L, Åhlin E, Sjöwall C, Skogh T, Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjogren's syndrome A antibodies. Clin Exp Immunol 2007, 147:513-520. 10.1111/j.1365-2249.2006.03313.x, 1810492, 17302901.
23. Mathsson L, Lampa J, Mullazehi M, Rönnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther 2006, 8:R64. 10.1186/ar1926, 1526644, 16569263.
24. Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003, 62:37-42. 10.1136/ard.62.1.37, 1754302, 12480667.